{"nodes":[{"data":{"id":"Complex_fa885e769bb2785e6e8e86c4c46a2f07","class":"complex","label":"NFkB Complex","parent":"nucleoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":24,"y":15,"w":52,"h":34},"metadata":[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177673.1"],["bp:id","R-HSA-177673"],["bp:db","reactome"]]],["bp:displayName","NFkB Complex"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Stoichiometry11383"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Stoichiometry11383"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Stoichiometry11383"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Stoichiometry11383"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Stoichiometry11383"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","Reactome DB_ID: 177673"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Complex4634"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Complex4634"]]}},{"data":{"id":"Protein_e77577507bfe7924491ff420182a75f8_Complex_fa885e769bb2785e6e8e86c4c46a2f07","class":"macromolecule","label":"RELA","parent":"Complex_fa885e769bb2785e6e8e86c4c46a2f07","clonemarker":false,"stateVariables":[{"class":"state variable","state":{"variable":"","value":"x[1 - 551]"}}],"unitsOfInformation":[],"bbox":{"x":24,"y":15,"w":48,"h":30},"metadata":[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177676.1"],["bp:id","R-HSA-177676"],["bp:db","reactome"]]],["bp:displayName","RELA"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1518"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","551"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3587"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3586"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1518"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q04206",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 529 529 Phosphoserine; by CK2."],["bp:featureLocation","MOD_RES 529 529 Phosphoserine; by CK2."]]],["bp:standardName","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:xref","Transcription factor p65"],["bp:organism","Transcription factor p65"],["bp:displayName","TF65_HUMAN"],["bp:name","NFKB3"],["bp:name","RELA"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5970"],["bp:comment","REPLACED ProteinRef_RELA__10116"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q04206-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5970"],["bp:comment","REPLACED ProteinRef_RELA__9606"],["bp:comment","REPLACED ProteinRef_RELA__10090"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-24238N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q04206_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5970"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1012"],["bp:comment","REPLACED ProteinRef_RELA__40674"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_068810"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andp65-c-Rel complexes are transcriptional activators. The NF-kappa-Bp65-p65 complex appears to be involved in invasin-mediatedactivation of IL-8 expression. The inhibitory effect of I-kappa-Bupon NF-kappa-B the cytoplasm is exerted primarily through theinteraction with p65. p65 shows a weak DNA-binding site whichcould contribute directly to DNA binding in the NF-kappa-Bcomplex. Associates with chromatin at the NF-kappa-B promoterregion via association with DDX1. Essential for cytokine geneexpression in T-cells (PubMed:15790681).{ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188,ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135,ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52complex. May interact with ETHE1. Binds AES and TLE1. Interactswith TP53BP2. Binds to and is phosphorylated by the activated formof either RPS6KA4 or RPS6KA5. Interacts with ING4 and thisinteraction may be indirect. Interacts with CARM1, USP48 andUNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts withNFKBID (By similarity). Interacts with NFKBIA. Interacts withGSK3B. Interacts with NFKBIB (By similarity). Interacts withNFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANKrepeats) (By similarity). Part of a 70-90 kDa complex at leastconsisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14.Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA.Interacts with HDAC1; the interaction requires non-phosphorylatedRELA. Interacts with CBP; the interaction requires phosphorylatedRELA. Interacts (phosphorylated at 'Thr-254') with PIN1; theinteraction inhibits p65 binding to NFKBIA. Interacts with SOCS1.Interacts with UXT. Interacts with MTDH and PHF11. Interacts withARRB2. Interacts with human respiratory syncytial virus (HRSV)protein M2-1. Interacts with NFKBIA (when phosphorylated), theinteraction is direct; phosphorylated NFKBIA is part of aSCF(BTRC)-like complex lacking CUL1. Interacts with RNF25.Interacts (via C-terminus) with DDX1. Interacts with UFL1 andCOMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interactswith MEN1; this interaction represses NFKB-mediatedtransactivation. Interacts with AKIP1, which promotes thephosphorylation and nuclear retention of RELA. Interacts (via theRHD) with GFI1; the interaction, after bacteriallipopolysaccharide (LPS) stimulation, inhibits the transcriptionalactivity by interfering with the DNA-binding activity to targetgene promoter DNA. Interacts (when acetylated at Lys-310) withBRD4; leading to activation of the NF-kappa-B pathway. Interactswith MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolyticcleavage of p65/RELA subunit and inhibition of NF-kappa-Btranscriptional activity (PubMed:18212740). Interacts with FOXP3.Interacts with CDK5RAP3; stimulates the interaction of RELA withHDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-Btranscriptional activity (PubMed:17785205).{ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:15790681,ECO:0000269|PubMed:17785205, ECO:0000269|PubMed:18212740}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Colocalized withDDX1 in the nucleus upon TNF-alpha induction (By similarity).Nuclear, but also found in the cytoplasm in an inactive formcomplexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 inthe nucleus after LPS stimulation. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=p65;IsoId=Q04206-1; Sequence=Displayed;Name=2; Synonyms=p65 delta 2;IsoId=Q04206-2; Sequence=VSP_005587, VSP_005588;Name=3; Synonyms=p65 delta;IsoId=Q04206-3; Sequence=VSP_012031;Name=4;IsoId=Q04206-4; Sequence=VSP_031245;Note=No experimental confirmation available.;DOMAIN: the 9aaTAD motif is a transactivation domain present in alarge number of yeast and animal transcription factors.{ECO:0000269|PubMed:17467953}.PTM: Ubiquitinated, leading to its proteasomal degradation.Degradation is required for termination of NF-kappa-B response.{ECO:0000269|PubMed:15226358}.PTM: Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes theformation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity.Phosphorylation at Ser-311 disrupts the interaction with EHMT1without preventing monomethylation at Lys-310 and relieves therepression of target genes (By similarity). {ECO:0000250}.PTM: Phosphorylation at Ser-311 disrupts the interaction withEHMT1 and promotes transcription factor activity (By similarity).Phosphorylation on Ser-536 stimulates acetylation on Lys-310 andinteraction with CBP; the phosphorylated and acetylated forms showenhanced transcriptional activity. Phosphorylation at Ser-276 byRPS6KA4 and RPS6KA5 promotes its transactivation andtranscriptional activities. {ECO:0000250,ECO:0000269|PubMed:10521409, ECO:0000269|PubMed:10938077,ECO:0000269|PubMed:11931769, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:14690596,ECO:0000269|PubMed:15073167, ECO:0000269|PubMed:15516339,ECO:0000269|PubMed:15775976, ECO:0000269|PubMed:16046471,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:16407239,ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:19103749}.PTM: Reversibly acetylated; the acetylation seems to be mediatedby CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA.Acetylation at Lys-310 is required for full transcriptionalactivity in the absence of effects on DNA binding and NFKBIAassociation. Acetylation at Lys-310 promotes interaction withBRD4. Acetylation can also lower DNA-binding and results innuclear export. Interaction with BRMS1 promotes deacetylation ofLys-310. Lys-310 is deacetylated by SIRT2.{ECO:0000269|PubMed:12419806, ECO:0000269|PubMed:12456660,ECO:0000269|PubMed:16135789, ECO:0000269|PubMed:17000776,ECO:0000269|PubMed:19103749}.PTM: S-nitrosylation of Cys-38 inactivates the enzyme activity.{ECO:0000250}.PTM: Sulfhydration at Cys-38 mediates the anti-apoptotic activityby promoting the interaction with RPS3 and activating thetranscription factor activity. {ECO:0000250}.PTM: Sumoylation by PIAS3 negatively regulates DNA-bound activatedNF-kappa-B. {ECO:0000269|PubMed:22649547}.PTM: Proteolytically cleaved within a conserved N-terminus regionrequired for base-specific contact with DNA in a CPEN1-mediatedmanner, and hence inhibits NF-kappa-B transcriptional activity(PubMed:18212740). {ECO:0000269|PubMed:18212740}.DISEASE: Note=A chromosomal aberration involving C11orf95 is foundin more than two-thirds of supratentorial ependymomas.Translocation with C11orf95 produces a C11orf95-RELA fusionprotein. C11orf95-RELA translocations are potent oncogenes thatprobably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).{ECO:0000269|PubMed:24553141}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/RELAID325.html\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/rela/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","TF65_HUMAN Reviewed; 551 AA."]]],["bp:name","NFkB3"],["bp:name","Nuclear factor NF-kappa-B p65 subunit"],["bp:name","Transcription factor p65"],["bp:comment","Reactome DB_ID: 177676"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1669"]]}},{"data":{"id":"Protein_f731fef637d2279198e3eb6a1ad8dda0_Complex_fa885e769bb2785e6e8e86c4c46a2f07","class":"macromolecule","label":"Nuclear factor NF-kappa-B","parent":"Complex_fa885e769bb2785e6e8e86c4c46a2f07","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":24,"y":12.5,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177655.1"],["bp:id","R-HSA-177655"],["bp:db","reactome"]]],["bp:displayName","NFkB1 p50"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1519"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","433"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3589"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3588"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1519"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:name","NFKB1(1-433)"],["bp:comment","Reactome DB_ID: 177655"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1670"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1670"]]],["bp:memberPhysicalEntity",[["bp:xref",[["bp:idVersion","1"],["bp:comment","Reactome stable identifier. Use this URL to connect to the web page of this instance in Reactome: http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-177655.1"],["bp:id","R-HSA-177655"],["bp:db","reactome"]]],["bp:displayName","NFkB1 p50"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005654"],["bp:db","gene ontology"]]],["bp:term","Nucleoplasm"],["bp:term","nucleoplasm"]]],["bp:feature",[["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#FragmentFeature1519"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","433"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3589"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceSite3588"]]],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#SequenceInterval1519"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P19838",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19838"]]],["bp:standardName","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:xref","Nuclear factor NF-kappa-B p105 subunit"],["bp:organism","Nuclear factor NF-kappa-B p105 subunit"],["bp:displayName","NFKB1_HUMAN"],["bp:name","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],["bp:name","NFKB1"],["bp:name","EBP-1"],["bp:name","DNA-binding factor KBF1"],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:comment","REPLACED ProteinRef_NFKB1__9606"],["bp:comment","FUNCTION: NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}.SUBUNIT: Component of the NF-kappa-B p65-p50 complex. Component ofthe NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50complex. Component of the NF-kappa-B p50-c-Rel complex. Componentof a complex consisting of the NF-kappa-B p50-p50 homodimer andBCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interactswith NCOA3 coactivator, which may coactivate NF-kappa-B dependentexpression via its histone acetyltransferase activity. Interactswith DSIPI; this interaction prevents nuclear translocation andDNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interactswith CFLAR; the interaction inhibits p105 processing into p50.NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2.Interacts with GSK3B; the interaction prevents processing of p105to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts withNFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts withNFKBID (By similarity). Directly interacts with MEN1. Interactswith HIF1AN. {ECO:0000250, ECO:0000269|PubMed:10469655,ECO:0000269|PubMed:11094166, ECO:0000269|PubMed:11468175,ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12393603,ECO:0000269|PubMed:12871932, ECO:0000269|PubMed:13679070,ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:14769797,ECO:0000269|PubMed:15102766, ECO:0000269|PubMed:15169888,ECO:0000269|PubMed:15485931, ECO:0000269|PubMed:17003112,ECO:0000269|PubMed:1740106, ECO:0000269|PubMed:8152812,ECO:0000269|PubMed:9315679, ECO:0000269|PubMed:9950430}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but alsofound in the cytoplasm in an inactive form complexed to aninhibitor (I-kappa-B).ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=P19838-1; Sequence=Displayed;Name=2;IsoId=P19838-2; Sequence=VSP_021025;Name=3;IsoId=P19838-3; Sequence=VSP_042869, VSP_042870;Note=No experimental confirmation available.;INDUCTION: By phorbol ester and TNF.DOMAIN: The C-terminus of p105 might be involved in cytoplasmicretention, inhibition of DNA-binding, and transcriptionactivation.DOMAIN: Glycine-rich region (GRR) appears to be a critical elementin the generation of p50.PTM: While translation occurs, the particular unfolded structureafter the GRR repeat promotes the generation of p50 making it anacceptable substrate for the proteasome. This process is known ascotranslational processing. The processed form is active and theunprocessed form acts as an inhibitor (I kappa B-like), being ableto form cytosolic complexes with NF-kappa B, trapping it in thecytoplasm. Complete folding of the region downstream of the GRRrepeat precludes processing. {ECO:0000269|PubMed:8628291}.PTM: Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 forproteolytic processing in response to TNF-alpha stimulation.Phosphorylation at 'Ser-927' and 'Ser-932' are required forBTRC/BTRCP-mediated proteolysis. {ECO:0000269|PubMed:11297557,ECO:0000269|PubMed:12482991, ECO:0000269|PubMed:12871932,ECO:0000269|PubMed:8628291}.PTM: Polyubiquitination seems to allow p105 processing.{ECO:0000269|PubMed:8087845, ECO:0000269|PubMed:8628291}.PTM: S-nitrosylation of Cys-61 affects DNA binding.{ECO:0000269|PubMed:11327828, ECO:0000269|PubMed:8710491}.PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur asan alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.DISEASE: Immunodeficiency, common variable, 12 (CVID12)[MIM:616576]: A primary immunodeficiency characterized by antibodydeficiency, hypogammaglobulinemia, recurrent bacterial infectionsand an inability to mount an antibody response to antigen.{ECO:0000269|PubMed:26279205}. Note=The disease is caused bymutations affecting the gene represented in this entry.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nfkb1/\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-106N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006714292"],["bp:comment","REPLACED http://identifiers.org/ncbigene/4790"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003989"],["bp:comment","NFKB1_HUMAN Reviewed; 968 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4790"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P19838-1"],["bp:comment","REPLACED http://identifiers.org/uniprot/D6RF93"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4790"],["bp:comment","REPLACED ProteinRef_NFKB1__10090"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1011"]]],["bp:name","Nuclear factor NF-kappa-B p50 subunit"],["bp:name","NFKB1(1-433)"],["bp:comment","Reactome DB_ID: 177655"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein1670"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein1670"]]],["bp:displayName","Nuclear factor NF-kappa-B"],["bp:cellularLocation","Nuclear factor NF-kappa-B"],["bp:entityReference_#ProteinReference_53cc86216ea0d5532957f9720675fd32","Nuclear factor NF-kappa-B"],["bp:comment","Converted from EntitySet in Reactome"],["bp:comment","Reactome DB_ID: 177662"],["bp:comment","REPLACED http://www.reactome.org/biopax/61/48887#Protein8907"],["bp:dataSource","REPLACED http://www.reactome.org/biopax/61/48887#Protein8907"]]}},{"data":{"id":"nucleoplasm","class":"compartment","label":"nucleoplasm","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":24,"y":15,"w":56,"h":38},"metadata":null}}],"edges":[],"pathwayMetadata":{"comments":["In contrast to NOD1/2 some NLRPs function as large macromolecular complexes called 'Inflammasomes'. These multiprotein platforms control activation of the cysteinyl aspartate protease caspase-1 and thereby the subsequent cleavage of pro-interleukin 1B (pro-IL1B) into the active proinflammatory cytokine IL1B. Activation of caspase-1 is essential for production of IL1B and IL18, which respectively bind and activate the IL1 receptor (IL1R) and IL18 receptor (IL18R) complexes. IL1R and IL18R activate NFkappaB and other signaling cascades.<br><br>As the activation of inflammasomes leads to caspase-1 activation, inflammasomes can be considered an upstream step of the IL1R and IL18R signaling cascades, linking intracellular pathogen sensing to immune response pathways mediated by Toll-Like Receptors (TLRs). Monocytes and macrophages do not express pro-IL1B until stimulated, typically by TLRs (Franchi et al. 2009). The resulting pro-IL1B is not converted to IL1B unless a second stimulus activates an inflammasome. This requirement for two distinct stimuli allows tight regulation of IL1B/IL18 production, necessary because excessive IL-1B production is associated with numerous inflammatory diseases such as gout and rheumatoid arthritis (Masters et al. 2009).<br><br>There are at least four subtypes of the inflammasome, characterized by the NLRP. In addition the protein AIM2 can form an inflammasome. All activate caspase-1. NLRP1 (NALP1), NLRP3 (Cryopyrin, NALP3), IPAF (CARD12, NLRC4) and AIM2 inflammasomes all have clear physiological roles in vivo. NLRP2, NLRP6, NLRP7, NLRP10 and NLRP12 have been demonstrated to modulate caspase-1 activity in vitro but the significance of this is unclear (Mariathasan and Monack, 2007).<br><br>NLRP3 and AIM2 bind the protein 'apoptosis-associated speck-like protein containing a CARD' (ASC, also called PYCARD), via a PYD-PYD domain interaction. This in turn recruits procaspase-1 through a CARD-CARD interaction. NLRP1 and IPAF contain CARD domains and can bind procaspase-1 directly, though both are stimulated by ASC. Oligomerization of NLRPs is believed to bring procaspases into close proximity, leading to 'induced proximity' auto-activation (Boatright et al. 2003). This leads to formation of the active caspase tetramer. NLRPs are generally considered to be cytoplasmic proteins, but there is evidence for cytoplasmic-nuclear shuttling of the family member CIITA (LeibundGut-Landmann et al. 2004) and tissue/cell dependent NALP1 expression in the nucleus of neurons and lymphocytes (Kummer et al. 2007); the significance of this remains unclear.","Edited: Jupe, S, 2011-04-28","Reviewed: Rittinger, K, 2011-06-06","Reviewed: Wong, Edmond, 2011-06-06","Reviewed: Kufer, TA, 2011-04-28","Authored: Jupe, S, 2010-04-22"],"dataSource":["Reactome"],"title":["Inflammasomes"]}}